Skip to main content
. 2017 Apr 12;17:263. doi: 10.1186/s12885-017-3272-y

Fig. 4.

Fig. 4

Serum KL-6 can predict the outcome of patients with lung adenocarcinoma. Receiver operating characteristic curves for (a) 1-year, (b) 3-year, and (c) 5-year survival. The Kaplan-Meier survival curves for each cohort stratified by the two different cut-off value of serum KL-6; (d) 600 U/mL (set by ROC analyses), (e) 334 U/mL (median value)